Ovarian hyperstimulation syndrome- An optimal solution for an unresolved enigma

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Orvieto, Raoul ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

GnRH agonist trigger; Ovarian hyperstimulation syndrome; Ovarian stimulation; Prediction; Prevention

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PROGESTERONE;

ASCITES; BLASTOCYST; CLINICAL OBSERVATION; CORPUS LUTEUM; DISEASE SEVERITY; EMBRYO TRANSFER; EMERGENCY HEALTH SERVICE; FEMALE; FERTILIZATION IN VITRO; FIRST TRIMESTER PREGNANCY; HIGH RISK PATIENT; HUMAN; LIVE BIRTH; LOW DRUG DOSE; LUTEAL PHASE; MULTIPLE PREGNANCY; NIDATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVULATION; OVULATION INDUCTION; PATIENT SAFETY; PREDICTIVE VALUE; PREGNANCY RATE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY PREVENTION;

EID: 84887033530     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-77     Document Type: Review

References (24)

1. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Navot D, Bergh PA, Laufer N, Fertil Steril 1992 58 249 261 1633889
2. Ovarian hyperstimulation syndrome: a new insight into an old enigma. Orvieto R, Ben-Rafael Z, J Soc Gynecol Invest 1998 5 110 113 10.1016/S1071-5576(97)00113-5 (Pubitemid 28248534)
3. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Kol S, Fertil Steril 2004 81 1 5 (Pubitemid 38058315)
4. Can we eliminate severe ovarian hyperstimulation syndrome? Orvieto R, Hum Reprod 2005 20 320 322 15567876 (Pubitemid 40277597)
5. An OHSS-Free Clinic by segmentation of IVF treatment. Devroey P, Polyzos NP, Blockeel C, Hum Reprod 2011 6 2593 2597
6. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM, Hum Reprod Update 2006 12 159 168 16254001 (Pubitemid 43239269)
7. Substituting HCG with GnRH agonist to trigger final follicular maturation-a retrospective comparison of three different ovarian stimulation protocols. Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R, Reprod Biomed Online 2006 13 198 201 10.1016/S1472-6483(10)60615-3 16895632 (Pubitemid 44207766)
8. GnRH agonist triggering: recent developments. Kol S, Humaidan P, Reprod Biomed Online 2013 26 226 230 10.1016/j.rbmo.2012.11.002 23337420
9. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin- releasing hormone antagonist protocol in combination with a 'freeze-all' strategy: a prospective multicentric study. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S, Fertil Steril 2011 95 2029 2033 10.1016/j.fertnstert.2011.01.163 21371705
10. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C, Fertil Steril 2008 89 84 91 10.1016/j.fertnstert.2007.02.002 17462639
11. Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Orvieto R, Reprod Biomed Online 2012 24 680 681 10.1016/j.rbmo.2012.03.005 22503268
12. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin- releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY, Fertil Steril 2010 93 847 854 10.1016/j.fertnstert.2008.12.042 19200959
13. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM, Reprod Biomed Online 2012 24 134 141 10.1016/j.rbmo.2011.11.001 22197130
14. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH, Hum Reprod 2013 28 9 2522 2528 10.1093/humrep/det124 23633553
15. The ovarian hyperstimulation syndrome. Navot D, Bergh PA, Laufer N, Reproductive Endocrinology, Surgery, and Technology Philadelphia: Lippincott-Raven Publishers, Adashi E, Rock JA, Rosenwaks Z, 1996 2215 2232
16. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: defnition of high risk groups. Asch RH, Lo HP, Balmaceda JP, Weckstein LN, Stone SC, Hum Reprod 1991 6 1395 1399 1770133
17. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P, Fertil Steril 2006 85 112 120 10.1016/j.fertnstert.2005.07.1292 16412740 (Pubitemid 43063432)
18. Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Orvieto R, Ben-Rafael Z, Hum Reprod 1998 13 3306 3309 10.1093/humrep/13.12.3306 9886504 (Pubitemid 29002612)
19. The possible role of intravenous immunoglobulin in preventing preeclampsia. Orvieto R, Achiron A, Ben-Rafael Z, Hagay Z, Achiron R, Med Hypoth 1993 41 160 164 10.1016/0306-9877(93)90063-V
20. Severe ovarian hyperstimulation syndrome despite low plasma estrogen levels in a hypogonadotropic hypogonadal patient. Levy T, Orvieto R, Homburg R, Dekel A, Peleg D, Ben-Rafael Z, Hum Reprod 1996 11 1177 1179 10.1093/oxfordjournals.humrep.a019350 8671418 (Pubitemid 26245309)
21. Elimination of ovarian hyperstimulatin syndrome. Orvieto R, Fertil Steril 2012 97 29 10.1016/j.fertnstert.2012.03.019 22503420
22. Prediction of OHSS-challenging the estradiol mitos. Orvieto R, Hum Reprod 2003 18 665 667 10.1093/humrep/deg166 12660254 (Pubitemid 36426940)
23. Ovarian hyperstimulation syndrome. The Practice Committee of the American Society for Reproductive Medicine (ASRM), Fertil Steril 2008 90 188 S193 19007627
24. Etiology of OHSS and use of dopamine agonists. Soares SR, Fertil Steril 2012 97 517 522 10.1016/j.fertnstert.2011.12.046 22265002